Prothrombotic state associated with preeclampsia

Han, Choong‐Hee; Chen, Yuanyuan; Dong, Jing‐fei

doi:10.1097/moh.0000000000000678

Cited by 13 publications

(5 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is suggested that unsuccessful transformation of uterine spiral arteries by trophoblasts in early pregnancy leads to poor placentation, causing hypoperfusion in the placental bed and fetal tissues, and as a result, placental factors released from the placenta into the maternal circulation lead to endothelial dysfunction, which is the main pathophysiology of preeclampsia 20 . This endothelial dysfunction creates a prothrombogenic predisposition and also increases the risk of thrombotic complications in these patients 21 .…”

Section: Discussionmentioning

confidence: 99%

Could signal peptide complement C1r/C1s, Uegf, and Bmp1, and epidermal growth factor-containing protein 1 be a therapeutic target in the pathogenesis of preeclampsia?

Toprak,

Yıldız,

Akdemir

et al. 2024

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

SUMMARY OBJECTIVE: Determination of biomolecules that play a role in the etiopathogenesis of preeclampsia and their application as therapeutic targets may increase surveillance in this patient group. The aim of this study was to investigate the relationship between signal peptide complement C1r/C1s, Uegf, and Bmp1, and epidermal growth factor-containing protein 1, a marker of endothelial dysfunction and platelet activation, and the development of preeclampsia. METHODS: In this observational cross-sectional study conducted between April 2021 and December 2022, 73 consecutive pregnant women with preeclampsia and 73 healthy pregnant women were included. Blood samples were taken from all patients with preeclampsia to measure signal peptide complement C1r/C1s, Uegf, and Bmp1, and epidermal growth factor-containing protein 1 levels at the time of hospitalization. Excluded from the study were pregnant women with certain medical conditions or treatments, and the signal peptide complement C1r/C1s, Uegf, and Bmp1, and epidermal growth factor-containing protein 1 levels of the groups were compared according to the development of preeclampsia. RESULTS: Signal peptide complement C1r/C1s, Uegf, and Bmp1, and epidermal growth factor-containing protein 1 levels were significantly higher in the preeclampsia group than in the controls (p<0.001). In multivariate analysis, signal peptide complement C1r/C1s, Uegf, and Bmp1, and epidermal growth factor-containing protein 1 was determined as an independent predictor for preeclampsia (OR: 1.678, 95%CI 1.424–1.979, p<0.001). Receiver operating characteristic curve analysis showed that the best cutoff value of signal peptide complement C1r/C1s, Uegf, and Bmp1, and epidermal growth factor-containing protein 1 at 3.25 ng/mL predicted the development of preeclampsia with 71% sensitivity and 68% specificity (area under the curve, 0.739; 95% confidence ınterval (95%CI), 0.681–0.798, p<0.001). CONCLUSION: Signal peptide complement C1r/C1s, Uegf, and Bmp1, and epidermal growth factor-containing protein 1 is significantly elevated in pregnant women with preeclampsia compared with healthy controls.

show abstract

Section: Discussionmentioning

confidence: 99%

Could signal peptide complement C1r/C1s, Uegf, and Bmp1, and epidermal growth factor-containing protein 1 be a therapeutic target in the pathogenesis of preeclampsia?

Toprak,

Yıldız,

Akdemir

et al. 2024

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

show abstract

“…Furthermore, there is a notable reduction in the surface expression of L-selectin (CD62L) on CD15+ neutrophils, which correlates with immune activation in PE [31]. Studies have shown that NETs can induce platelet activation and a prothrombotic state during PE [28,32]. This body of evidence suggests that neutrophils are activated and potentially primed for NET release in PE, both in the microcirculation and periphery, contributing to a feedback loop involving inflammation and endothelial dysfunction.…”

Section: Activation Of Neutrophils In Pementioning

confidence: 99%

Targeting Neutrophil Extracellular Trap Formation: Exploring Promising Pharmacological Strategies for the Treatment of Preeclampsia

Hernández González,

Pérez-Campos Mayoral,

Hernández-Huerta

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Neutrophils, which constitute the most abundant leukocytes in human blood, emerge as crucial players in the induction of endothelial cell death and the modulation of endothelial cell responses under both physiological and pathological conditions. The hallmark of preeclampsia is endothelial dysfunction induced by systemic inflammation, in which neutrophils, particularly through the formation of neutrophil extracellular traps (NETs), play a pivotal role in the development and perpetuation of endothelial dysfunction and the hypertensive state. Considering the potential of numerous pharmaceutical agents to attenuate NET formation (NETosis) in preeclampsia, a comprehensive assessment of the extensively studied candidates becomes imperative. This review aims to identify mechanisms associated with the induction and negative regulation of NETs in the context of preeclampsia. We discuss potential drugs to modulate NETosis, such as NF-κβ inhibitors, vitamin D, and aspirin, and their association with mutagenicity and genotoxicity. Strong evidence supports the notion that molecules involved in the activation of NETs could serve as promising targets for the treatment of preeclampsia.

show abstract

“…The majority of the modifications in coagulation result in hypercoagulability, which protects the mother from excessive bleeding after delivery or miscarriage [16]. Hypercoagulability, endothelial damage, and venous stasis all contribute to the prothrombotic state that is pregnancy [17]. This hypercoagulable state is the most important predictor of thrombosis during pregnancy.…”

Section: Hemostasis In Pregnancymentioning

confidence: 99%

Elevated factor VIII level: An implication for thrombosis during pregnancy

Chikamso Favour Agbo,

Freedom Amarachi Nkwocha,

Reuben Chukwuma Odo

et al. 2023

Open Access Res. J. Life Sci.

View full text Add to dashboard Cite

Hemostasis is the process by which the body maintains the integrity of blood vessels and regulates blood circulation. It involves arresting bleeding, and possibly mending broken or severed blood vessels. It is achieved through a series of steps, including vascular spasm, platelet plug formation, coagulation cascade, and fibrinolysis. Skipping any of these steps causes severe bleeding and death. During pregnancy, the hemostatic system undergoes significant changes to adapt to the physiological demands. These changes aim to prevent excessive bleeding during and after childbirth. Hypercoagulability, characterized by elevated clotting factors and reduced fibrinolytic activity, is common during pregnancy. While these alterations in the coagulation system help prevent postpartum bleeding, they also increase the mother's risk of thrombosis by a factor of five. This hypercoagulable state is caused by pregnancy-related factors like venous stasis, endothelial damage, and hormonal fluctuations. However, studies have shown that an increase in Factor VIII levels poses as a risk factor for both venous and arterial thrombosis. The determination of plasma factor VIII levels is influenced by genetic factors, as well as the levels of von Willebrand factor (VWF) and the individual's blood group. The findings of familial investigations have revealed that the concentration of factor VIII is indeed hereditary, exhibiting a lesser degree of variability among twins when compared with individuals who lack a familial connection. Continuous monitoring should be performed on pregnant patients with thrombosis risk factors. This intervention is implemented with the aim of mitigating the potential aggravation of deep vein thrombosis (DVT) and the subsequent development of post-thrombotic syndrome.

show abstract

Prothrombotic state associated with preeclampsia

Cited by 13 publications

References 120 publications

Could signal peptide complement C1r/C1s, Uegf, and Bmp1, and epidermal growth factor-containing protein 1 be a therapeutic target in the pathogenesis of preeclampsia?

Could signal peptide complement C1r/C1s, Uegf, and Bmp1, and epidermal growth factor-containing protein 1 be a therapeutic target in the pathogenesis of preeclampsia?

Targeting Neutrophil Extracellular Trap Formation: Exploring Promising Pharmacological Strategies for the Treatment of Preeclampsia

Elevated factor VIII level: An implication for thrombosis during pregnancy

Contact Info

Product

Resources

About